Pulsatile & Structural
Surgical repair of a defect in the bony wall of the sigmoid sinus — an alternative to stenting for one specific, imaging-confirmed cause of pulsatile tinnitus.
Evidence strength: Limited (2/5) · Tier 3 — experimental/emerging · Evidence independence: Primarily independent.
For PULSATILE tinnitus caused by a sigmoid sinus wall anomaly (dehiscence or diverticulum seen on imaging), a surgeon rebuilds the bony wall between the venous sinus and the ear, blocking transmission of the blood-flow sound. It treats the same family of vascular causes as venous sinus stenting, from the outside rather than inside the vein.
Uncontrolled series report elimination of the pulsatile sound in most correctly selected patients (pooled 77.6% complete resolution; 83.8% durable at 5+ years in the longest cohort; ~65% under stricter definitions). Rated moderate, not strong: no controlled data, and outcome definitions vary widely.
Distress typically resolves with the sound, but series rarely measure THI/TFI systematically.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
Uncontrolled surgical case series only (no RCT, no comparative trial vs stenting): pooled complete resolution 77.6% in a systematic review, 97.3% short-term / 83.8% at 5+ years in the longest cohort — but with 9.3% significant complications, 13.5% recurrence, and new intracranial-hypertension diagnoses in 8.6%. Resolution rates drop (to ~65% in one cohort) under stricter outcome definitions. High apparent effect in a narrow, imaging-confirmed subgroup; low certainty by design.
Sathya A, et al. (SR); Ahanotu AE, et al. (long-term cohort) · Interventional Neuroradiology / Otology & Neurotology · 2024 · N=SR: 105 patients/107 diverticula (surgical); cohort: 35 patients/37 ears · Systematic review of case series + long-term single-center cohort (no RCTs)
Surgical complete resolution 77.6% (incomplete 11.2%; significant complications 9.3%) across pooled series; long-term cohort: 97.3% short-term success, 83.8% at 5+ years, 13.5% recurrence, new intracranial-hypertension diagnoses in 8.6%. A stricter-criteria critical review puts complete elimination at 64.9% in one cohort.
All evidence is uncontrolled surgical series — resolution rates depend heavily on how 'resolution' is defined. Comparative SR: endovascular treatment of the same lesions resolved 27/27 with fewer complications (3.7%). Key risks: intracranial hypertension/papilledema, recurrence, need for subsequent stenting.
Limited independent. Consistent high resolution rates across several independent surgical centers — but every series is uncontrolled, so what replicates is the case-series pattern, not a controlled effect.
Safety evidence: Limited. Real surgical risks: significant complications in 9.3% of pooled cases; intracranial hypertension/papilledema can emerge after reconstruction (new IIH diagnosed in 8.6% of the long-term cohort; some patients later needed venous stenting); recurrence 13.5%.
Regulatory status: Surgical procedure (no device approval applicable). Standard otologic/neurosurgical techniques; no dedicated device.
Availability: Tertiary otology/neurotology centers after full imaging workup · Europe: Same · Cost (approx.): Surgical-procedure costs; often covered when medically indicated
Evidence last reviewed: 2026-09-04 · Evidence included through: 2026-09-04 · Confidence: moderate. Open the interactive evidence profile · How we rate evidence.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.